Premier Fund Managers’s MaxCyte MXCT Stock Holding History

Premier Fund Managers’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,800	Closed	-$113K	–	221
2023 Q3	$113K	Sell	35,800 -72,327	-67%	-$291K	0.01%	195
2023 Q2	$485K	Sell	108,127 -76,745	-42%	-$353K	0.02%	191
2023 Q1	$868K	Sell	184,872 -70,523	-28%	-$347K	0.03%	184
2022 Q4	$1.37M	Hold	255,395	–	–	0.05%	154
2022 Q3	$1.6M	Buy	+255,395	New	+$1.42M	0.12%	89

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Premier Fund Managers's MXCT Position: Q4 2023 in Review

Premier Fund Managers sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 35,800 shares — an estimated $113K sold.

Premier Fund Managers first reported a position in MXCT in Q3 2022 and held it in 5 quarters. The position peaked at $1.6M in Q3 2022. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

Premier Fund Managers reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
Premier Fund Managers sold 35,800 MaxCyte shares in Q4 2023, an estimated $113K.
Premier Fund Managers first reported a position in MaxCyte in Q3 2022 and held it in 5 quarters.
Premier Fund Managers's MaxCyte position peaked at $1.6M in Q3 2022.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Premier Fund Managers's 13F filing for Q4 2023, filed 13 Feb 2024.